RT Journal Article
SR Electronic
T1 New Strategies in Colorectal Cancer: Biomarkers of Response to Epidermal Growth Factor Receptor Monoclonal Antibodies and Potential Therapeutic Targets in Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Pathways
JF Clinical Cancer Research
JO Clin Cancer Res
FD American Association for Cancer Research
SP 3811
OP 3818
DO 10.1158/1078-0432.CCR-09-2283
VO 16
IS 15
A1 Dasari, Arvind
A1 Messersmith, Wells A.
YR 2010
UL http://clincancerres.aacrjournals.org/content/16/15/3811.abstract
AB Initial experience with the epidermal growth factor receptor monoclonal antibodies (EGFR MoAb) in unselected patients with metastatic colorectal cancer (mCRC) showed that most of the treated patients did not derive therapeutic benefit. This outcome has driven the search for biomarkers for this population. Recent advances have further shown the heterogeneous nature of this disease with multiple interlinked pathways being implicated. Two such pathways downstream to the EGFR, mitogen-activated protein kinase (MAPK) and (phosphoinositide 3-kinase) PI3K, have gained increasing attention and become targets for development of novel biomarkers and therapeutic agents. Here, we highlight recent progress. Clin Cancer Res; 16(15); 3811–8. ©2010 AACR.